Stockreport

Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

Kronos Bio, Inc.  (KRON) 
PDF Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742 $270.3 mil [Read more]